Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A transgenic non-human mammal or a portion thereof, wherein an α-synuclein gene is introduced and the gene is expressed in the neurons, and the number of dopamine-producing neurons in the substantia nigra is significantly decreased as compared with that of a wild-type animal.

2. (Original) The transgenic non-human mammal or a portion thereof according to claim 1, wherein the α-synuclein gene is a human α-synuclein gene or a variant thereof.

3. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~or 2~~, wherein the α-synuclein gene is a variant of a wild-type human α-synuclein gene in a manner that substitutes a Thr residue for an Ala residue at amino acid residue 53 in an amino acid sequence encoded by the wild-type human α-synuclein gene.

4. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 3~~, wherein the α-synuclein gene is a gene that is varied from a wild-type α-synuclein gene in a manner that deletes C terminal amino acid residues encoded by the wild-type α-synuclein gene.

5. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 4~~, wherein a recombinant DNA incorporating the α-synuclein gene therein under the control of a promoter capable of expressing the α-synuclein gene in the dopamine-producing neurons is introduced.

6. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 5~~, wherein the promoter capable of expressing the α-synuclein gene in the dopamine-producing neurons is a tyrosine hydroxylase promoter.

7. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 6~~, wherein an intracerebral dopamine level at an early age is significantly decreased as compared with that of a wild-type animal.

8. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 7~~, wherein an intracerebral dopamine level at an early age is decreased to 85% or less as compared with that of a wild-type animal.

9. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 8~~, wherein a tyrosine hydroxylase expression level is decreased to 80% or less as compared with that of a wild-type animal.

10. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 9~~, wherein a spontaneous locomotor activity is decreased to 60% or less as compared with that of a wild-type animal.

11. (Currently Amended) The transgenic non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 10~~, wherein the non-human mammal is a mouse.

12. (Currently Amended) A method for screening a substance having dopamine-like action wherein the non-human mammal or a portion thereof according to claim 1 ~~any of claims 1 to 11~~ is used.

13. (Original) The screening method according to claim 12, wherein the substance having dopamine-like action is a therapeutic agent or preventive agent for Parkinson's disease.

14. (Currently Amended) A substance obtained by the screening method according to claim 12 ~~or 13~~.

15. (Currently Amended) A therapeutic agent or preventive agent for Parkinson's disease which comprises a substance obtained by the screening method according to claim 12 ~~or 13~~, as an active ingredient.